These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37553211)

  • 1. The Emerging Role of the Single-Cell and Spatial Tumor Microenvironment in High-Grade Serous Ovarian Cancer.
    Launonen IM; Vähärautio A; Färkkilä A
    Cold Spring Harb Perspect Med; 2023 Oct; 13(10):. PubMed ID: 37553211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
    Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response.
    Yang H; Gu X; Fan R; Zhu Q; Zhong S; Wan X; Chen Q; Zhu L; Feng F
    J Ovarian Res; 2023 Nov; 16(1):223. PubMed ID: 37993916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatial Transcriptomics Depict Ligand-Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors.
    Ferri-Borgogno S; Zhu Y; Sheng J; Burks JK; Gomez JA; Wong KK; Wong STC; Mok SC
    Cancer Res; 2023 May; 83(9):1503-1516. PubMed ID: 36787106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.
    Shakfa N; Li D; Conseil G; Lightbody ED; Wilson-Sanchez J; Hamade A; Chenard S; Jawa NA; Laight BJ; Afriyie-Asante A; Tyryshkin K; Koebel M; Koti M
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37015760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
    McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR
    Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
    Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
    APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer.
    Zhang C; Cao K; Yang M; Wang Y; He M; Lu J; Huang Y; Zhang G; Liu H
    Oncoimmunology; 2023; 12(1):2261242. PubMed ID: 37791232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
    Wan C; Keany MP; Dong H; Al-Alem LF; Pandya UM; Lazo S; Boehnke K; Lynch KN; Xu R; Zarrella DT; Gu S; Cejas P; Lim K; Long HW; Elias KM; Horowitz NS; Feltmate CM; Muto MG; Worley MJ; Berkowitz RS; Matulonis UA; Nucci MR; Crum CP; Rueda BR; Brown M; Liu XS; Hill SJ
    Cancer Res; 2021 Jan; 81(1):158-173. PubMed ID: 33158814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status.
    Whitehair R; Peres LC; Mills AM
    Int J Gynecol Pathol; 2020 Nov; 39(6):558-566. PubMed ID: 31851060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomics of High-Grade Serous Ovarian Cancer Models Identifies Cancer-Associated Fibroblast Markers Associated with Clinical Outcomes.
    Govindarajan M; Ignatchenko V; Ailles L; Kislinger T
    Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes.
    Ardighieri L; Missale F; Bugatti M; Gatta LB; Pezzali I; Monti M; Gottardi S; Zanotti L; Bignotti E; Ravaggi A; Tognon G; Odicino F; Calza S; Missolo-Koussou Y; Ries CH; Helft J; Vermi W
    Front Immunol; 2021; 12():690201. PubMed ID: 34220848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of the immune microenvironment in ovarian cancer patients.
    Yang L; Wang S; Zhang Q; Pan Y; Lv Y; Chen X; Zuo Y; Hao D
    Mol Omics; 2018 Oct; 14(5):341-351. PubMed ID: 30129640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
    Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
    J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer.
    McGray AJR; Huang RY; Battaglia S; Eppolito C; Miliotto A; Stephenson KB; Lugade AA; Webster G; Lichty BD; Seshadri M; Kozbor D; Odunsi K
    J Immunother Cancer; 2019 Jul; 7(1):189. PubMed ID: 31315674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status.
    Corvigno S; Burks JK; Hu W; Zhong Y; Jennings NB; Fleming ND; Westin SN; Fellman B; Liu J; Sood AK
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3545-3555. PubMed ID: 34476576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.
    Niu N; Shen W; Zhong Y; Bast RC; Jazaeri A; Sood AK; Liu J
    Hum Pathol; 2021 Jul; 113():20-27. PubMed ID: 33887301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic Changes in the Extracellular Matrix in Primary, Metastatic, and Recurrent Ovarian Cancers.
    Gertych A; Walts AE; Cheng K; Liu M; John J; Lester J; Karlan BY; Orsulic S
    Cells; 2022 Nov; 11(23):. PubMed ID: 36497028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer.
    Cao K; Zhang G; Yang M; Wang Y; He M; Zhang C; Huang Y; Lu J; Liu H
    Cancer Res; 2023 Jul; 83(13):2171-2186. PubMed ID: 37172314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.